Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase IIa, Dose-Finding Study of Ad5.F35-hGCC-PADRE Vaccine in Adults With Gastrointestinal Adenocarcinomas at Risk of Relapse Post Definitive Surgery and Standard Therapy

Summary

The purpose of this phase IIa study is to evaluate the safety and tolerability as well as cellular response of Ad5.F35-hGCC-PADRE vaccine delivered intramuscularly in patients with colorectal, pancreatic, gastric, or esophageal cancers who are at high risk of relapse without evidence of disease post definitive surgery and standard therapy.

General Information

NCT#: NCT04111172
Study ID: 19P.785
Trial Phase: Phase II

Trial Sponsor: Thomas Jefferson University
Therapies Used in This Trial: Ad5.F35-hGCC-PADRE

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search